Robert Paratte
Analyst · your question.
Sure. Jamie, just – again, starting with Seattle. The life science hub in Seattle, the place to be the South Lake Union and similar to Oyster Point, as well as our UTC locations, you have these competing forces of tech companies and life science companies and this is somewhat of a generalization. But life science companies are going to cluster around universities in the same way that tech companies do. So right now in Seattle, BioMed has a project, there's very little current supply. It's hard to find sites for life science. And I think another phenomenon that may change or life science maybe forced to change the way they operate is the tech is much more nimble and much more agile. And they end up signing leases quicker than life science companies do. I gave that example earlier about the life science company in South San Francisco that's signed in December. It's a different way of operating and they need to be more nimble and it's very difficult. There are secondary markets outside of the cluster area that I would call South Lake Union. But where Kilroy wants to be is where there is supply constraints, where it's harder to get sites and where you can drive rents. So South San Francisco, as I mentioned, we're tracking 2.2 million square feet of supply, two-thirds of that is already leased. BioMed will have the only ground-up construction, shell and core complete end of this year. And I gave you an example again earlier about the 180 different companies, biotech companies in that market and it's unrelenting. I mean, we’re tracking about 3.5 million square feet of demand right now for tenants. And our project specifically, Oyster Point, we've been very active in presentations and zoom meetings and some physical onsite presentations to companies. So we're feeling very good about that. And again, talking about clusters, you really only have South San Francisco, and then you have parts of San Mateo County. But the life science market in the Bay Area really kind of stops at Palo Alto. So it's hard to imagine going back to John's point about conversions and that sort of thing that you'll see life science leapfrog into San Jose for example, even though there's R&D type product that maybe able to be converted, that's not where they want to be. And then San Diego, particularly UTC, where vacancy is about 1.4%, I mentioned earlier the theme, and I just mentioned it now, too. You've got these competing forces of tech versus life science and it's literally a race for space. So hopefully that gives you some color.